ArticleGenes and immunity2026
Heparin inhibits NLRP3-dependent pyroptosis in acute pancreatitis.
Article in Genes and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ameliorative effects of heparin on acute pancreatitis (AP) have received widespread attention. NLRP3 inflammasome-dependent pyroptosis has been reported to be a key factor contributing to AP development. However, it remains unclear whether heparin alleviates AP by modulating NLRP3 inflammasome-dependent pyroptosis. An AP model was established in vivo and in vitro using Sprague Dawley rats and AR42J cells. TUNEL and propidium iodide staining assessed cell death. Cellular pyroptosis was observed under a microscope. Intermolecular interactions were verified using Co-IP and RIP assays. The m6A level of KAT2B was assessed by MeRIP. Levels of pro-inflammatory factors were determined using ELISA. Our results showed that heparin attenuated AP in vivo by inhibiting NLRP3-mediated pyroptosis. VIRMA expression was increased in AP. Meanwhile, overexpression of VIRMA reversed the alleviating effect of heparin on cellular pyroptosis. KAT2B knockdown counteracted the promotion of pyroptosis by VIRMA. Mechanically, VIRMA promoted KAT2B mRNA stability in an m6A-ELAVL1-dependent manner, whereas KAT2B upregulation further promoted NLRP3 acetylation at K694. The wild-type NLRP3 reversed the inhibitory of heparin on pyroptosis, and KAT2B amplified this regulatory effect. Taken together, heparin prevented cellular pyroptosis by inhibiting the VIRMA-mediated m6A modification of KAT2B, which in turn inhibited NLRP3 acetylation at K694, ultimately attenuating AP.
Indexed as
Identifiers
41857374What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.